GlassScriptPhysician profile
Han S Koh
NPI 1720057326
$9,691.19
in general payments reported to CMS, 2019-2025
37 companies · $1,584 in 2025
The $1,584 reported for 2025 was more than what a typical Neurology (Psychiatry & Neurology) provider received nationally (typical 2025 total: $454).
See the full distribution for Neurology (Psychiatry & Neurology)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $738 · 2020: $1,001 · 2021: $2,192 · 2022: $1,950 · 2023: $1,069 · 2024: $1,157 · 2025: $1,584.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,666 · Education: $145.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,665.78 |
| Education | $144.98 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Celgene Corporation | $1,141.89 | 2020-2025 | Zeposia |
| Novartis Pharmaceuticals Corporation | $965.52 | 2020-2025 | |
| Alexion Pharmaceuticals, INC. | $894.78 | 2019-2025 | Ultomiris |
| Abbvie INC. | $855.84 | 2021-2025 | |
| Amgen INC. | $527.64 | 2020-2022 | |
| Lilly USA, LLC | $502.18 | 2019-2025 | Kisunla |
| E.R. Squibb & Sons, L.L.C. | $470.25 | 2020-2022 | |
| Teva Pharmaceuticals USA, INC. | $455.95 | 2019-2022 | |
| Biogen, INC. | $434.17 | 2019-2022 | |
| Genzyme Corporation | $427.68 | 2019-2022 | |
| Biohaven Pharmaceuticals, INC. | $347.65 | 2021 | |
| Eisai INC. | $346.55 | 2022-2025 | |
| Pfizer INC. | $325.24 | 2023-2025 | |
| Acadia Pharmaceuticals INC | $263.60 | 2019 | |
| Neurocrine Biosciences, INC. | $234.06 | 2020-2025 |
Show all 37 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sk Life Science, INC. | $180.85 | 2023 | Xcopri |
| Astrazeneca Pharmaceuticals LP | $176.12 | 2024-2025 | Wainua |
| Harmony Biosciences LLC | $144.98 | 2024-2025 | |
| Tg Therapeutics, INC. | $113.98 | 2025 | |
| Argenx US, INC. | $83.79 | 2025 | Vyvgart, Vyvgart Hytrulo |
| Sunovion Pharmaceuticals INC. | $82.39 | 2021-2022 | |
| Biohaven Pharmaceutical Holding Company LTD. | $77.15 | 2022 | |
| Vanda Pharmaceuticals INC. | $74.16 | 2025 | Ponvory |
| Impel Pharmaceuticals INC. | $70.22 | 2022 | |
| Emd Serono, INC. | $62.02 | 2019 | |
| Jazz Pharmaceuticals INC. | $57.16 | 2025 | |
| Sanofi-Aventis U.S. LLC | $55.49 | 2020-2021 | |
| Lundbeck LLC | $53.46 | 2025 | Vyepti |
| Ucb, INC. | $52.41 | 2025 | Rystiggo |
| Mallinckrodt Enterprises LLC | $39.54 | 2019 | |
| Axsome Therapeutics, INC. | $37.45 | 2025 | Symbravo |
| Inspire Medical Systems, INC. | $26.58 | 2025 | Inspire |
| Ani Pharmaceuticals, INC. | $25.07 | 2024 | Purified Cortrophin Gel |
| Supernus Pharmaceuticals, INC. | $25.04 | 2019-2020 | |
| Mallinckrodt Hospital Products INC. | $23.47 | 2020 | |
| Horizon Therapeutics Plc | $22.26 | 2021 | |
| Strongbridge US INC. | $14.60 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Han Koh listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.